The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | Adapting MRD monitoring to each patient with AML based on their disease profile
In this video, Francesco Buccisano, MD, University of Rome Tor Vergata, Rome, Italy, advises physicians on adapting measurable residual disease (MRD) testing to the specific biological profile of each patient with acute myeloid leukemia (AML). Dr Buccisano recommends using MRD evaluation at specific and validated time points, such as after two cycles of intensive chemotherapy and pre-transplant, and potentially in the post-transplant phase to monitor graft-versus-leukemia (GVL) effect. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The general policy of the ELN, European Leukemia Networking Party, dealing with the MRD in AML, is suggesting to adapt to every specific biological profile of AML patients a specific test for MRD determination. This means, for instance, that patients with a balanced translocation will be followed up by RT-qPCR. The new NGS-PCR will be targeted to patients affected with the FLT3-ITD AML and multi-parameter flow cytometry will monitor MRD in all other patients categories...
The general policy of the ELN, European Leukemia Networking Party, dealing with the MRD in AML, is suggesting to adapt to every specific biological profile of AML patients a specific test for MRD determination. This means, for instance, that patients with a balanced translocation will be followed up by RT-qPCR. The new NGS-PCR will be targeted to patients affected with the FLT3-ITD AML and multi-parameter flow cytometry will monitor MRD in all other patients categories.
What we suggest is to use the MRD evaluation in specific and validated time points. This means after two cycles of intensive chemotherapy and pre-transplant. And further exploratory aim of MRD monitoring is in the post-transplant phase, where it may be a trigger for a pre-emptive treatment of impending relapse and maybe a measurement of the GVL, graft versus leukemia effect of the transplant itself.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Speakers bureau: Jazz, Delbert, Servier, Novartis, Menarini.
